ERBB4 and oral cavity cancer: Similarly, the metastatic gene Erbb4 was found to be mutated at a slightly increased rate of 3.70% in MSK-IMPACT oral cavity cancer vs. 2.88% in TCGA-HNC oral cavity cancer (as well as notable Erbb4 mutations in 5.88% (1/17 cases) of nasopharyngeal cancer, 12.50% (1/8 cases) of salivary gland cancer, 12.50% (1/8 cases) of other squamous cell carcinomas (SCCs) of the head and neck, and 11.11% (1/9 cases) of cancers of unknown primary in the head and neck region, as annotated by MSK-IMPACT (https://www.cbioportal.org/study/summary?id=msk_impact_2017; Table S9).